ATAI

AtaiBeckley Inc.
CAPPED RATING

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

AtaiBeckley Inc. (ATAI) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.7 / 5.0
D+
Value
F
Factor Score 0.2 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
D
Factor Score 1.2 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -15.3
EV / EBITDA -17.8
Rev Growth YoY 137.0%
Gross Margin 0.0%
Price Return 3M N/A
Price Return 12M N/A
Catalyst Signal 0.00
Market Cap $2.7B
TTM Revenue $4.5M
Price / Sales 609.5
ROE -417.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 F (0.2) C- (2.1) D (1.2) C+ (2.5) C+ (2.6) D+ (1.7)
2026-11-10 F (0.1) C- (2.1) D (1.2) C+ (2.5) F (0.0) D (1.2)
2026-11-03 F (0.2) C- (2.1) D (1.2) C+ (2.5) F (0.0) D (1.2)
2026-10-27 F (0.3) C- (2.1) D (1.2) C+ (2.5) F (0.0) D (1.2)
2026-10-20 F (0.3) C- (2.1) D (1.2) C+ (2.5) F (0.0) D (1.2)
Page 1 of 5